CONTEXT AND OBJECTIVE: Cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) are associated with tumorigenesis. Studies have shown that HER-2 can regulate COX-2 expression. The aim of this study was to evaluate the correlation between COX-2 and HER-2 expression in normal breast epithelium and in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) present in the same breast. DESIGN AND SETTING: Cross-sectional study at the Mastology Unit of the Department of Gynecology and Obstetrics, Santa Casa de Misericórdia de São Paulo Hospital. METHODS: COX-2 and HER-2 were detected using immunohistochemistry on 100 tissue fragments. HER-2 ≥ +2 was subjected to fluorescence in situ hybridization (FISH). RESULTS: COX-2 expression was detected in 87%, 85% and 75% of IDC, DCIS and normal epithelium, respectively. HER-2 expression was detected in 34% of IDC and 34% of DCIS. COX-2 in DCIS correlated with HER-2 in IDC (P = 0.049) and DCIS (P = 0.049). COX-2 in normal epithelium correlated with HER-2 in IDC (P = 0.046) and DCIS (P = 0.046). COX-2 in IDC was not associated with HER-2 (P = 0.235). Comparison between COX-2 and HER-2 in DCIS showed that there was a statistically significant difference with regard to nuclear grades II and III and presence of comedonecrosis (P < 0.001). In IDC, there was significant expression with nuclear grades II and III and histological grade II (P < 0.001). CONCLUSIONS: Our findings provide evidence that HER-2 and COX-2 regulate each other.
INTRODUCTION
Prostaglandins are known to participate in multiple physiological and pathological processes, including wound healing, cardiovascular disease, inflammation and the development and growth of malignant tumors. 1 Cyclooxygenase-2 (COX-2), the inducible isoform of prostaglandin H synthase, has been implicated in the origin of a variety of human cancers, including breast, colon, lung, gastric, skin, endometrial, ovarian and esophageal adenocarcinomas. 2,3 COX-2 seems to be involved in the processes of malignant transformation and tumor progression by affecting cell proliferation, mitosis, cell adhesion, apoptosis, immune surveillance, angiogenesis and formation of carcinogenic metabolites such as malondialdehyde. 4, 5 Breast cancer is the most common cancer in women and is the second biggest cause of cancer-related mortality in the world. 6 Epidemiological studies have suggested that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) may have some protective effect against breast cancer. 7 Significantly reduced risk of human breast cancer relating to intake of selective COX-2 inhibitors has been reported. 8 COX-2 expression is induced by pro-inflammatory cytokines, tumor promoters, growth factors and viral transformation. 9, 10 How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate chemopreventive effects are issues that still need further clarification.
Another important protein, closely related to breast cancer, is human epidermal growth factor receptor type 2 (HER-2), one of the four receptors belonging to the HER family. 11, 12 This receptor presents proliferation-stimulating responses upon ligand binding. 13 HER-2 overexpression often results from increased c-erb-b2 gene activation. 14, 15 Its overexpression becomes more important when this protein forms heterodimers with other HER family receptors, such as human epidermal growth factor receptor type 3 (HER-3). This leads to hyperactive cell signaling pathways and the emergence of a situation of uncontrolled cell proliferation, thus culminating in tumorigenesis. 16 Overexpression of this protein in breast cancer has been associated with disease aggressiveness, a more reserved prog- Many studies have already analyzed HER-2 and COX-2 expression in ductal carcinoma in situ and invasive ductal carcinoma, but most of these studies were carried out on samples from different women, thereby restricting the usefulness of these data for studying tumor progression.
OBJECTIVE
The aim of this study was to evaluate the correlation between COX-2 and HER-2 expression in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) from the same breast as well as in normal epithelium. Additionally, we also correlated protein expression with nuclear grade, histological grade, presence or absence of comedonecrosis, tumor size (smaller or equal to 2 cm or greater than 2 cm) and age at time of diagnosis (younger than 50 years or 50 years and over). The slides were then rinsed in PBS, and the biotinylated secondary antibody was applied at room temperature for 30 minutes (Dako Corp., California, United States). The slides were incubated in streptavidin-peroxidase at 37 °C for 30 minutes.
METHODS

Sample collection
The specimens were rinsed in 0.005% Tween-20 in PBS and then incubated with the 3.3´-diaminobenzidine chromogenic substrate for five minutes. The sections were counterstained in
Meyer`s hematoxylin and were then mounted.
HER-2 fluorescence in situ hybridization (FISH) analysis
Tumors that were scored +2 for membranous staining using the Dako HercepTest kit were subjected to FISH analysis using the 
Evaluation of COX-2 and HER-2 staining
COX-2 and HER-2 immunohistochemical staining were evaluated and scored independently and blindly by two investigators.
For COX-2, we used the same criteria adopted by Ris- Sections were scored by one investigator and subjected to review by a second investigator.
Statistical analysis
The correlation between COX-2 and HER-2 was analyzed using 
RESULTS
COX-2 expression
One hundred cases were evaluated for immunoreactivity with anti-COX-2 antibodies. COX-2 immunoreactivity was characteristically cytoplasmic and granular. COX-2 was positively detected at frequencies of 87%, 85% and 75% in IDC, DCIS and normal epithelium respectively. We found in tumors of sizes less than or equal to 2 cm that COX-2 expression significantly correlated with HER-2 in IDC, DCIS and normal epithelium (P < 0.03). In tumors larger than 2 cm, there was also significantly higher expression of COX-2 and HER-2 in IDC, DCIS and normal epithelium (P < 0.001) ( Table 2 and Table 3 ).
In spite of age, for patients aged 50 years or over, COX-2 and HER-2 expression was statistically significant in IDC, DCIS and normal epithelium (P < 0.001). In patients less than 50 years of age, again, COX-2 and HER-2 expression was statistically significant in IDC and DCIS (P = 0.005), and in normal epithelium (P < 0.001) ( Table 4 and Table 5 ).
DISCUSSION
Research studies examining the tumor microenvironment are providing information on the molecular mechanisms behind the role played by inflammation in initiating or promoting a wide range of cancers. This has important implications for prevention, monitoring and treatment. In this manner, the enzyme COX-2 is emerging as an important biological marker, among other agents.
24,25
The exact mechanisms through which COX-2 is upregu- Table 1 . Association of expression of human epidermal growth factor receptor type 2 (HER-2) and cyclooxygenase-2 (COX-2) in non-neoplastic ducts, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of the same breast and statistical analysis by the Spearman correlation (R) least partially be reverted through the use of COX inhibitors.
Studies have shown that it is even possible to revert tamoxifen resistance in specific breast cancer cells through the use of NFkB inhibitors, 30 and to observe a direct correlation between NFkB activity and HER-2/neu expression, thereby suggesting a possible role for COX activity in tumor progression. 26 In breast cancer cases, the constitutive activity of NFkB causes losses in estrogen receptor and resistance antibody-based therapies, Table 3 . Expression of cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) in 100 cases, in tumors larger than 2 cm and statistical analysis using the chi-square test Table 4 . Expression of cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) in 100 patients aged 50 years or over and statistical analysis using the chi-square test The expression of the markers examined was analyzed in relation to classic clinicopathological parameters, in the presence and absence of tamoxifen. HER-2 and COX-2 were both found to be predictive of poor disease-free survival in patients on endocrine treatment. Positive COX-2 status among the patients was found to be predictive of adverse effects from tamoxifen. These clinical ex vivo data are consistent with molecular observations that HER-2 can regulate COX-2 expression through direct transcriptional mechanisms. COX-2 expression correlates with disease progression on endocrine treatment. This study supports a role for COX-2 as a predictor of adverse effects from tamoxifen in breast cancer patients. 31 Other authors studied tissue samples from 64 women with breast cancer to examine the levels of transcripts of COX-2 and 12-lipoxygenase and to compare between the expressions of the two enzymes. They found that 41% of the cases examined exhibited Table 5 . Expression of cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) in 100 patients less than 50 years of age and statistical analysis using the chi-square test COX-2 expression in DCIS correlated with tumor aggressiveness, since the expression level was found to be higher in nuclear grade III tumors and in those presenting comedonecrosis. With regard to IDC, COX-2 expression was also higher in nuclear grade III tumors. Our data corroborate the findings reported by other authors. 32, 35 In parallel, we studied HER-2 and found that 34% of the IDC and DCIS cases were positive for this protein.
Our results are concordant with a variety of findings described for other invasive carcinomas. [28] [29] [30] We observed that when there were two tumor components (DCIS and IDC) in the same paraffin block, the rate of positivity for HER-2 seemed to be the same for the two regions (34% and 34%). As expected, analysis on normal epithelium did not show HER-2 expression through immunohistochemical staining.
We found that HER-2 in DCIS had greater expression in nuclear grade III tumors and in those presenting comedonecrosis.
Moreover, HER-2 expression in IDC was statistically significant in relation to nuclear grade III and histological grade. Also with regard to IDC, COX-2 expression was higher in nuclear grade III tumors. Our results suggest that these were situations of tumor aggressiveness, since the expression level for HER-2 was higher.
Similar data have also been described by other authors. 11, 12, 14, 15 Comparison of high levels of COX-2 expression and high levels of HER-2 expression in DCIS, according to different nuclear grades and the presence of comedonecrosis, showed that there was statistically significant expression between the two proteins with regard to nuclear grades II and III and the presence of comedonecrosis (P < 0.001). When focusing on IDC, we found significantly positive expression with nuclear grades II and III and histological grade II between COX-2 and HER-2 (P < 0.001).
We found in tumors of sizes less than or equal to 2 cm that COX-2 expression significantly correlated with HER-2 in IDC, DCIS and normal epithelium (P < 0.03). In tumors larger than 2 cm, there was also significantly higher expression of COX-2 and HER-2 in IDC, DCIS and normal epithelium (P < 0.001).
In spite of age, for patients aged 50 years or over, COX-2 and HER-2 expression was statistically significant in IDC, DCIS and normal epithelium (P < 0.001). In patients less than 50 years of age, again, COX-2 and HER-2 expression was statistically significant in IDC and DCIS (P = 0.005), and in normal epithelium (P < 0.001).
Several studies have addressed the expression of HER-2 and COX-2 in breast cancer. The exact molecular mechanism behind the coexpression of these two proteins is not completely understood yet, although some insights exist. 26, 31, 32 We compared the expression of COX-2 and HER-2 in breast cancers by means of immunohistochemistry and FISH. Our observations indicate that there is a highly significant correlation between COX-2 expression and HER-2 expression, both in IDC and in DCIS. In addition, we studied the expression of this protein in non-neoplastic ducts (normal epithelium) and we did not obtain any statistical correlation between COX-2 and HER-2 expression. We hypothesize that higher COX-2 expression correlates with higher HER-2 expression. This hypothesis is consistent with the findings from this study. Our results are in agreement with those obtained by Boland et al., 24 Perrone et al., 36 Subbaramaiah et al., 18 Benoit et al., 37 Cho et al., 38 Dillon et al. 31 and Mohamed et al. 32 One current point of discussion is that effects linked with the expression level of this protein, such as nuclear grade, histological grade, presence of comedonecrosis, tumor size and age at the time of diagnosis are also due to independent mechanisms for COX-2 and HER-2. In our study, high levels of COX-2 protein were reported more frequently in breast cancer cases with overexpressed of HER-2 when DCIS and IDC were both present in the same breast. The fact that our analysis was performed in simultaneous tumors might account for the higher levels of expression found; consequently, a direct relationship between COX-2 and HER-2 might be more readily observed. In addition, the level of HER-2 expression may correlate with activity levels and the ability to induce COX-2. 21 The mechanisms through which COX-2 and HER-2 expression is upregulated in these processes are unclear, and many pathways and factors are known to be involved in carcinogenesis.
CONCLUSIONS
From analysis of our results, we could confirm that there is a positive correlation between COX-2 and HER-2 in DCIS and IDC.
Breast cancer cases with high levels COX-2 expression showed the presence of HER-2 expression in DCIS and CDI and these two enzymes did not show expression in normal ephitelium.
